The anti-apoptotic molecule Aven was originally identified in a yeast two-hybrid screen for Bcl-x L -interacting proteins and has also been found to bind Apaf-1, thereby interfering with Apaf-1 self-association during apoptosome assembly. Aven is expressed in a wide variety of adult tissues and cell lines, and there is increasing evidence that its overexpression correlates with tumorigenesis, particularly in acute leukemias. The mechanism by which the anti-apoptotic activity of Aven is regulated remains poorly understood. Here we shed light on this issue by demonstrating that proteolytic removal of an inhibitory N-terminal Aven domain is necessary to activate the anti-apoptotic potential of the molecule. Furthermore, we identify Cathepsin D (CathD) as the protease responsible for Aven cleavage. On the basis of our results, we propose a model of Aven activation by which its N-terminal inhibitory domain is removed by CathD-mediated proteolysis, thereby unleashing its cytoprotective function.
Two important apoptosis signal-transduction pathways have been delineated in recent years. Whereas the extrinsic pathway is exclusively triggered by activation of a specific subclass of the TNF receptor superfamily, the so-called death receptors, an important and integral part of the intrinsic mitochondrial apoptosis pathway involves the release of several pro-apoptotic molecules, including Cyt c, from the mitochondria into the cytosol.
1,2 Subsequent Cyt c/dATPdependent formation of the Caspase-9-activating apoptosome protein complex requires oligomerization of the adaptor protein Apaf-1 for Caspase-9 recruitment and activation. 3, 4 To prevent the severe patho-physiological consequences of the deregulation of mitochondrial apoptosis, apoptosome activity is tightly regulated. Defects in the mitochondrial apoptosis pathway have been linked to various pathologies such as heart attack, stroke, liver failure, autoimmune diseases and cancer (for a review see D'Amelio et al., 5 Hajra and Liu, 6 and Ledgerwood and Morison 7 ). Failure to form a functional apoptosome complex and initiate the caspase cascade by activating Caspase-9 contributes to tumor development, the progression of several malignancies and also has a significant role in the development of cancer therapy resistance. Therefore, tight regulation of apoptosome activation is critical for normal homeostasis.
Several intracellular apoptosis inhibitors have been reported to prevent Apaf-1 oligomerization, for example, prothymosin alpha (ProT 8, 9 ) and the heat shock proteins 70 and 90. [10] [11] [12] Another anti-apoptotic molecule with apoptosome-regulating activity is Aven. Although initially identified in a yeast two-hybrid screen for Bcl-x L -interacting proteins, 13 Aven has also been found to bind to Apaf-1, thereby interfering with Apaf-1 self-association during apoptosome assembly. Whether the interaction of Aven with Bcl-x L contributes to its anti-apoptotic activity 14 or it is in fact dispensable 13 remains an open question. Interestingly, two recent publications have reported increased Aven protein levels in acute leukemias. Aven overexpression was found to be associated with poor prognosis in childhood acute lymphoblastic leukemia, and it has been suggested as a novel prognostic indicator in these malignancies. 15, 16 These correlative studies suggest a potential oncogenic role for the anti-apoptotic protein Aven in acute leukemias.
Since the original report published by Chau et al., 13 no additional information regarding the molecular mechanism of apoptosis inhibition by Aven has been reported. In particular, the mechanism by which the activity of this ubiquitous apoptosis inhibitor is controlled remains unclear, as Aven is expressed in a wide variety of adult tissues and cell lines. In this study, we demonstrate that for the activation of its anti-apoptotic potential the inhibitory Aven N-terminus must be cleaved by Cathepsin D (CathD). Therefore, it is the proteolytic processing by CathD rather than the absolute expression levels that determine the anti-apoptotic potential of Aven within the cell, a finding that may have implications for therapeutic targeting of Aven activity during tumorigenesis.
Results
Deletion of the N-terminus is required for efficient inhibition of mitochondrial apoptosis by the antiapoptotic protein Aven. We performed a functional yeast survival screen with a human breast carcinoma-derived cDNA library in order to identify novel anti-apoptotic proteins involved in tumorigenesis. 17, 18 Among others, we isolated a cDNA clone coding for an N-terminal deletion mutant of the anti-apoptotic Aven protein. This clone, which efficiently suppressed yeast cell death induced by the proapoptotic C. elegans protein CED-4 (see Supplementary  Figure 1 ), lacks the coding sequence for the N-terminal 179 aa (amino acid) of the protein (DN-Aven 180-362). The construct most likely represents an artifact generated during library production rather than a naturally occurring transcript of a truncated Aven isoform, as no splicing sites are predicted at or near the gene region where the 5 0 end of DN-Aven 180-362 is located.
To analyze the anti-apoptotic potential of DN-Aven 180-362 in a mammalian cell system, human colon carcinoma type II 19 RKO cells were transfected with plasmids coding for either the full-length Aven or DN-Aven 180-362 and subsequently treated with the death stimulus Fas Ligand (FasL). Surprisingly, transfection of full-length Aven did not protect against FasL-induced cell death, whereas DN-Aven 180-362 significantly inhibited apoptosis (Figure 1a) . We also investigated the potential of Aven and DN-Aven 180-362 to inhibit The mean values of three independent experiments (each in duplicate) are shown. A one-way ANOVA test was performed with a LSD/ Bonferroni post-hoc analysis to test for significant differences between the two constructs (at varying concentrations of mitomycin C). The variations between the Flag-Aven, Flag-DN-Aven 180-362, and Bcl-x L results are highly significant at 4.5 and 7 mg/ml mitomycin C (Pr0.001). (c) Caspase-3 activity was measured in extracts derived from the HEK 293T cells previously transfected with empty vector pcDNA3.1 (pc3.1), full-length Flag-Aven, Flag-DN-Aven 180-362, or XIAP (Caspase-3 inhibitor). Cell lysates were incubated in the presence ( þ ) or absence (À) of Cyt c and dATP to induce apoptosome formation. Caspase-3 activity was then quantified fluorometrically upon cleavage of the added DEVD-AFC substrate.
The mean values of eight independent experiments (each performed in triplicate) are shown. The mean Caspase-3 activity in lysates containing Flag-DN-Aven 180-362 was significantly decreased compared to lysates of cells transfected with pcDNA3.1 or Flag-Aven (Pr0.001, One-way ANOVA with Games-Howell post-hoc analysis). The bars in a-c represent standard errors with ** and *** indicating Pr0.01 and Pr0.001, respectively cell death induced by mitomycin C, a potent DNA crosslinker used in cancer treatment to induce mitochondrial apoptosis. 20, 21 Figure 1b shows that DN-Aven 180-362 and the bona fide apoptosis inhibitor Bcl-x L both significantly inhibited apoptosis caused by mitomycin C at different concentrations, whereas expression of full-length Aven did not confer protection under this experimental paradigm.
Failure of full-length Aven to inhibit apoptosis was confirmed by measuring Caspase-3 activity in the cell lysates prepared from transfected human embryonic kidney (HEK) 293T cells that were subsequently activated for apoptosome formation by addition of exogenous Cyt c and dATP. Using this in vitro system, we found that upon activation, lysates from cells transfected with Flag-tagged full-length Aven displayed levels of Caspase-3 activity that were similar to those of the control lysates (i.e., cells that had been transfected with empty vector; see Figure 1c ). In contrast, lysates from cells overexpressing Flag-tagged DN-Aven 180-362 showed significantly lower levels of Caspase-3 activity when compared with control lysates, displaying values comparable to those obtained with lysates from cells overexpressing the caspase inhibitor XIAP.
The inhibitory Aven N-terminus is removed by CathD-dependent cleavage. Our results suggest that the Aven N-terminus yields an inhibitory influence, which requires neutralization before the protein is capable of exerting its anti-apoptotic activity. As DN-Aven 180-362 most likely represents a cloning artifact generated during cDNA library production, we analyzed different cell lines in search for naturally occurring smaller Aven isoforms. Full-length Aven was also overexpressed in the mammary adenocarcinoma cell line MCF-7 and in HEK 293T cells, and protein expression was subsequently analyzed via immunoblot assay using an antibody that specifically recognizes the C-terminus of Aven (Aven CT). Expression analysis revealed that in addition to the full-length Aven protein, a further immunoreactive band of B30 kDa was present in cell lysates, which is similar in size to the artificial DN-Aven 180-362 (see Figure 2a) . Interestingly, this truncated form of Aven lacking the N-terminus occasionally appears as a doublet in MCF-7 cells (between 26 and 30 kDa), whereas only one band is detected in 293T cells (bands labeled with arrowheads). We confirmed the specificity of these bands in MCF-7 cells by knocking down Aven expression. Although both the endogenous full-length Aven protein and the 30-kDa C-terminal Aven fragment were detected in cells transduced with a lentiviral control vector, they were either significantly reduced or absent in cells stably transduced with Aven shRNA (Figure 2b) .
The presence of a truncated form of Aven in two independent cell lines suggests that Aven could be subjected to intracellular processing. To test whether a protease was responsible for generating the 30-kDa Aven fragment, we treated MCF-7 cells with various protease inhibitors (Figure 2c ). While incubation with the cysteine protease inhibitor E64 22 and the caspase inhibitor z-VAD 23 showed no influence on Aven processing, the serine protease inhibitor aprotinin 24 and the serine and cysteine protease inhibitor pAPMSF 25 both significantly hampered the production of the 30-kDa C-terminal Aven form. Interestingly, treating cells with pepstatin A, an inhibitor of aspartic proteases and specifically of CathD, 26 entirely abolished Aven cleavage, thereby leading to a complete absence of the 30-kDa Aven fragment ( Figure 2C, upper panel) . A dose-response experiment using various concentrations of pepstatin A confirmed that 10 mM of the inhibitor is sufficient to substantially suppress Aven proteolysis (Figure 2c, lower panel) .
CathD is a prominent member of the subfamily of lysosomal aspartic proteases, and its enzymatic function is not restricted solely to the acidic milieu of lysosomes (for a review see Liaudet-Coopman et al. 27 and Masson et al. 28 ). CathD has been implicated in positive and negative regulation of apoptosis, and its overexpression has been reported to promote tumorigenesis and metastasis of breast cancer (for a review see Masson et al. 28 and Garcia et al. 29 ). Using lentiviral shRNA constructs we investigated whether CathD was required for Aven processing. Remarkably, stable knockdown of CathD in MCF-7 cells by the CathD shRNA CD1 resulted in a complete absence of the endogenous 30-kDa C-terminal DN-Aven fragment (see Figure 2d We performed a cleavage assay using recombinant human CathD and His-tagged full-length Aven protein purified from HEK 293T cells to investigate whether Aven represents a direct CathD target. At pH 6.5, CathD treatment generated a 30-kDa C-terminal fragment from full-length Aven, which could be detected by western blot analysis in a timedependent manner ( Figure 3a) . Addition of the CathD inhibitor pepstatin A prevented the formation of the truncated Aven form, and incubation for two hours without recombinant CathD failed to result in cleavage of the full-length Aven protein (data not shown). Thus, CathD can directly cleave Aven, thereby resulting in the generation of a 30-kDa DN-Aven fragment.
To define the exact CathD cleavage sites, we analyzed a CathD digest of purified His-tagged Aven protein, both in the presence and absence of pepstatin A, using a mass spectrometry-based positional proteomics approach. The cleavage of proteins by proteases generates new alpha-N-termini (on the C-terminal fragments that are created), and these new primary amino groups can be marked with small tags that are easily identified following mass spectrometry and a database search. Here, the primary amino groups introduced by the CathD cleavage of Aven were chemically labeled with a trideutero-acetyl group (note that the epsilon-amines on lysines are also modified by the same group). Subsequent further processing by trypsin (performed to generate peptides that are identifiable by MS/MS) yields two classes of peptides: N-trideutero-acetylated protein N-terminal peptides and internal peptides holding a primary, non-trideutero-acetylated amino group. The former directly suggests processing by CathD, whereas the latter simply indicates the presence of Aven protein in the sample. According to this analysis, in the absence of peptstatin A, Aven was cleaved by CathD at sites located between aa 144/145 and between aa 196/197 (see Figure 3b ). Both cleavage sites (together with the binding sites of the antisera used in this study) are indicated in the schematic diagram of Aven protein shown in Figure 3c . Taken together, these data strongly suggest that the cleaved Aven molecules observed in cells are direct products of CathD-mediated cleavage.
Aven and CathD partly co-localize in endosomal particles. Proteolytic removal of the inhibitory Aven N-terminus by CathD can only occur with endogenous proteins in vivo if both proteins co-localize within the cell during the processing of Aven. To investigate whether endogenous Aven and CathD co-localize intracellularly we performed immunofluorescence studies using MCF-7 cells. As expected, CathD staining resulted in a characteristic punctuate pattern typical of lysosomal/endosomal localization ( Figure 4 , upper panels). Interestingly, although Aven appears evenly distributed in small vesicles within the cytosol, the protein was also localized to larger punctuate structures in approximately 3-5% of the cells (Figure 4 , middle panels). Aven staining in these larger vesicular structures frequently overlapped with CathD staining (Figure 4 , lower panels, see arrows). These results indicate that in MCF-7 cells, a fraction of Aven protein is co-localized in or at vesicular compartments with CathD, a prerequisite for physical interaction between Aven and its activating protease in vivo.
Aven expression and proteolytic CathD activity are required to inhibit Caspase-3 activation in MCF-7/ Casp-3 cells. To investigate the link between the CathDmediated proteolysis of Aven and its ability to regulate apoptosis we first treated MCF7/Casp-3 cells (i.e., MCF-7 cells stably expressing transgenic Caspase-3 30 ) with pepstatin A. As shown in Figure 5a , inhibition of CathD A comparable increase in Caspase-3 activity as seen with pepstatin A-treated cells was observed when we abolished the expression of either Aven or CathD via stable shRNA transduction (Figure 5b) . Interestingly, the levels of increased caspase activation were similar for both single knockdowns, again suggesting that these manipulations may affect the same pathway. Indeed, the simultaneous double knockdown of both Aven and CathD did not lead to additional increases in Caspase-3 activity as compared with both single knockdowns (data not shown).
The inhibitory N-terminus is involved in Aven selfinteractions. Our results demonstrate that the N-terminal portion of Aven exerts an inhibitory influence on the anti-apoptotic function of the molecule (see Figure 1) . We hypothesized that the regulation of Aven activity could be a result of either intra-or intermolecular Aven-Aven interactions mediated by the N-terminus. To test whether this protein region mediates self-interaction we performed co-immunoprecipitation experiments with various Flagtagged Aven deletion constructs and a GFP-tagged version of the full-length Aven. As shown in Figure 6 , full-length Aven-GFP protein efficiently co-precipitated with both the full-length Flag-Aven and the Flag-N-Aven 1-180 proteins, whereas the truncated Flag-DN-Aven 180-362 mutant lacking the N-terminus was unable to interact with Aven-GFP. Taken together, these experiments indicate that Figure 4 Aven co-localizes with CathD in cytosolic vesicles. Immunofluorescence analysis was performed in fixed MCF-7 cells with goat anti-human CathD antibody and rabbit anti-human Aven B (recognizing aa 256-268), followed by detection with appropriate secondary antibodies. CathD shows staining in endosomal compartments (upper panels) whereas Aven displays a fine vesicular cytosolic staining pattern (middle panels). Some cells also display a larger punctuate Aven staining that overlaps with CathD signals (lower panels; Aven: red, CathD: green)
CathepsinD Aven
Aven is capable of homomeric interactions, and the N-terminus of the protein is necessary for self-association.
Discussion
Aven has been reported as an anti-apoptotic molecule that prevents apoptosome formation by directly binding to Apaf-1. 13 However, the mechanism by which the deathsuppressing activity of this ubiquitously expressed protein is regulated remains unclear. In this study, we demonstrated the following: (i) the presence of an inhibitory N-terminal domain in Aven that downregulates its anti-apoptotic capacity; (ii) proteolytic removal of this inhibitory domain in intact cells, On the basis of our data, we propose a model of Aven activation by which its N-terminal inhibitory domain is removed by CathD-mediated cleavage, thereby unleashing Aven's cytoprotective activity. Our data establish that cleavage of Aven yielding the protective DN-Aven fragment is CathD-dependent. Because we demonstrated the cleavage of purified Aven with the recombinant protease at positions aa 144/145 and aa 196/197 by mass spectrometry analysis (Figure 3) , it is very likely that CathD directly hydrolyzes Aven, especially as this cleavage can be inhibited by the addition of pepstatin A. Both cleavage sites identified by mass spectrometry displayed processing events adjacent to Leu residues, which correlates with the specificity of CathD activity. 31 In general, cathepsins recognize stretches within their substrates rather than well-defined recognition sites (FI and KG, personal communication), and are therefore expected to cleave at multiple sites. The results obtained from the western blot analysis presented in Figure 2e Although CathD is one of the most abundant lysosomal proteases, several studies have also demonstrated the presence of active CathD outside the lysosomes. CathD is overexpressed and hyper-secreted by epithelial breast cancer cells where it promotes various cellular processes, including the degradation of basement membranes (for a review see Liaudet-Coopman et al. 27 ). CathD also activates specific substrates in the pre-lysosomal endosome compartment (for a review see Garcia et al. 29 ). In addition, large intracellular acidic vesicles found in both breast cancer cell lines and primary tumors contain phagocytosed extracellular material and high levels of CathD, which has the potential to degrade or activate important signaling molecules. 32 Interestingly, a fine vesicular cytoplasmic staining pattern consistent with intracellular membrane localization has been reported for Aven, a finding that was supported by immunoblot analyses of fractionated cells. 13 Aven was associated primarily with the light-membrane fraction and was absent from the soluble S-100 fraction. These data are consistent with our immunofluorescence results that indicate that a portion of the Aven molecules is co-localizing with CathD in or at vesicular compartments ( Figure 4) .
Alternatively, Aven may also be cleaved by CathD in the cytoplasm. It has been reported that CathD is released from lysosomes into the cytosol at the early onset of apoptosis, thereby leading to the mitochondrial release of Cyt c and caspase activation (for a review see Masson et al. 28 ). However, it can be envisaged that before activating the prodeath machinery, CathD must first activate anti-apoptotic proteins (e.g., Aven) in the cytosol to delay death and to allow for damage repair. In that regard, the overexpression of endogenous CathD typically observed in breast cancer cells 28 may lead to a constant release of CathD into the cytoplasm, thereby resulting in the activation of anti-death molecules such as Aven, and rendering tumor cells resistant to apoptosis. This notion is supported by the increased production of endogenous DN-Aven observed in the breast cancer cell line MCF-7 ( Figure 2b , left lane; endogenous DN-Aven was also detected in longer exposures of Figure 2a blots, in empty vector-transfected cells (data not shown)).
The mechanism by which the N-terminal domain inhibits the anti-apoptotic activity of the Aven molecule remains to be elucidated. We found that the N-terminus can bind to fulllength-Aven and that proteins lacking this domain lose their binding ability. It is possible that Aven self-association results in conformational changes or domain masking that interferes with the capacity of the full-length protein to inhibit apoptosis. In this scenario, the removal of the N-terminus by CathD would eliminate such inhibitory self-interactions and restore the full anti-apoptotic potential of Aven. The interaction of Aven with Bcl-x L is unlikely to provide insight into the capability of DN-Aven to suppress cell death as Chau et al. 13 have already mapped the Bcl-x L binding site on the Aven molecule between aa 74 and 104. Therefore, in contrast to the fulllength Aven protein, the anti-apoptotic DN-Aven (lacking a larger N-terminal portion of Aven than the first 104 aa) is not able to bind to Bcl-x L , as we have demonstrated by coimmunoprecipitation (data not shown), thereby indicating that the molecular mechanism by which CathD cleavage of Aven protects cells against apoptosis is independent of Bcl-x L . However, our data do not rule out the possibility that Aven may inhibit apoptosis by more than one molecular mechanism. Moreover, under certain conditions and/or cellular systems, full-length Aven may enhance the protective potential of Bcl-x L .
14 As far as the interaction of Aven with Apaf-1 is concerned, we could show by co-immunoprecipitation that DN-Aven is still able to bind to Apaf-1, as is full-length Aven (data not shown). Although this interaction underlines the notion that Aven inhibits the mitochondrial apoptosis pathway, the protein may also exert other non-apoptotic cell-survival functions.
As the Aven N-terminus exhibits inhibitory characteristics it is interesting to note that mice express a shorter Aven transcript lacking most of the N-terminus (Acc. no. NM_001165935.1). Both mRNA and protein expression levels of this murine Aven variant and its functional relevance have not been investigated.
Aven has also been reported to function in DNA damage repair and G 2 /M cell-cycle progression. 33 The addition of Aven mRNA coding for either the full-length or DN72 human Aven protein (the latter lacking the N-terminal 72 aa) to cycling Xenopus egg extracts resulted in ATM kinase activation and the inhibition of mitotic entry. Similar effects were observed after the addition of purified recombinant His-tagged DN72 Aven protein. It will be interesting to investigate whether the ATM-activating function of Aven also requires the removal of its N-terminus by CathD.
In essence, our results indicate that it is the proteolytic removal of Aven's N-terminus by CathD rather than the Aven expression level, which represents the major bottleneck in the generation of anti-apoptotic Aven activity. Therefore, Aven should be classified along with other proteins such as caspases and the Bcl-2 family member Bid (for a review see Ola et al. 34 ), which require post-translational regulation by proteolytic processing to execute their apoptosis-regulating function.
Material and Methods
Cell culture, transfections and reagents. The human colorectal carcinoma cell line RKO (ATCC CCL-2) and HEK 293T cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Life Technologies, Darmstadt, Germany), while the human breast adenocarcinoma cell line MCF-7 (no Caspase-3 expression; ATCC HTB-22) and MCF-7/Casp-3 cells (MCF-7 cells stably transfected with Caspase-3) were cultured in 1640 Roswell Park Memorial Institute (RPMI) medium (Gibco). Both types of medium were supplemented with 10% fetal bovine serum (Sigma Aldrich, Munich, Germany), 4 mM L-glutamine (PAA Laboratories GmbH, Cölbe, Germany), penicillin and streptomycin (1 Â from stock solution; PAA Laboratories GmbH). The cells were kept in an atmosphere of 5% CO 2 at 37 1C. MCF-7 and MCF-7/Casp-3 cells were kindly provided by R Jänicke (University of Düsseldorf, Germany).
RKO and MCF-7 cells were transfected with Lipofectamine (Invitrogen, Life Technologies, Darmstadt, Germany) and 293T cells were transfected with PEI (polyethyleneimine, Sigma Aldrich) according to the manufacturers' instructions. Protease inhibitors pepstatin A (Sigma Aldrich), E-64 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), z-VAD (Sigma), aprotinin and pAPMSF (both Santa Cruz Biotechnology) were dissolved in DMSO (Roth, Karlsruhe, Germany) and used at the concentrations indicated in the text.
Expression constructs. The following N-terminally Flag-tagged human Aven mutants were generated by PCR and cloned into pcDNA3.1 ( þ ) Zeo (Invitrogen): full-length Aven (aa 1-362; kindly provided by M Rimpler (MDC Berlin, Germany)), DN-Aven (aa 180-362) and N-Aven (aa 1-180). In addition, full-length Aven with a C-terminal 10 Â His-tag was generated by PCR and cloned into the pcDNA3.1( þ ) Zeo (pcDNA3.1 flAven-10xHis) vector. Full length Aven was cloned into a variant of the mammalian GFP expression vector pEGFP-N1 (Clontech, Saint-Germain-en-Laye, France). pEBB-HA-XIAP was kindly provided by GM Cohen (MRC Toxicology Unit, University of Leicester, Leicester, UK), and pcDNA3.1( þ ) Zeo His-Bcl-X L was provided by R Eskes (Molecular Hematology, University Clinic Frankfurt, Frankfurt, Germany).
shRNA constructs and lentiviral transduction. The lentiviral pLKO.1 puro shRNA (Sigma) construct sequences for Aven and CathD downregulation are as follows:
Aven shRNA: 5 0 -CCGGGAGAATGATGAACAGGGAAATCTCGAGATTTCCCT GTTCATCATTCTCTTTTTTG-3 0 ; Control (scrambled) shRNA: 5 0 -CCGGCAACAAG ATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT-3 0 ; CathD shRNA CD1: 5 0 -CCGGCATCACCTTCATCGCAGCCAACTCGAGTTGGCTGCGAT GAAGGTGATGTTTTT-3 0 ; CathD shRNA CD2: 5 0 -CCGGACCTCGTTTGACATCCA CTATCTCGAGATAGTGGATGTCAAACGAGGTTTTTT-3 0 . Lentiviral transduction was performed by transfection of 1.5 Â 10 6 HEK 293T cells per 10 cm dish with 2.5 mg pLKO.1 puro shRNA vector, together with the packaging vectors pMDG2 (1.625 mg) and 8.91 (0.875 mg) and polyethyleneimine. Supernatants were harvested after 48 and 72 h and used directly for lentiviral transduction. MCF-7/Casp-3 cells were seeded (2 Â 10 5 cells/well) in 6-well plates 1 day before transduction. Lentivirus-containing supernatants were mixed with 8 mg/ml polybrene and added directly onto the cells. Cells were transduced during centrifugation at 1000 r.p.m. and 32 1C for 80 min and subsequently incubated at 37 1C/5% CO 2 . Supernatants were exchanged for fresh medium after 4-6 h, and the transduction was repeated on the next day. Cells were grown to confluence and subject to puromycin selection (2 mg/ml) from the first passage onward.
Antibodies. The primary antibodies used are as follows: mouse monoclonal anti-Flag (M2, Sigma), rabbit polyclonal anti-Aven CT (cProSci, raised against a 14-aa C-terminal peptide located in the region between aa 335 and aa 362 of the human Aven protein), mouse monoclonal anti-GFP (Stressgen Biotechnologies, Enzo Life Sciences, Lörrach, Germany), goat polyclonal anti-CathD (R&D Systems, Wiesbaden, Germany), anti-Ezrin (Invitrogen), anti-Aven A (aa 98-112) and antiAven-B (aa 256-268 (the latter two were a kind gift from JM Hardwick, John Hopkins University, Baltimore, MD, USA)). Fluorochrome-conjugated species-specific secondary antibodies for immunofluorescence were obtained from Jackson ImmunoResearch (West Grove, PA, USA). For immunoblot experiments, antimouse IgG, anti-rabbit IgG (Amersham Biosciences, GE Healthcare, Munich, Germany) and anti-mouse kappa light chain (Zymed, Life Technologies, Darmstadt, Germany) coupled to horseradish peroxidase were used as secondary anti-species antibodies.
Apoptosis detection by flow cytometry. RKO cells were transiently transfected with either control or Aven constructs and incubated overnight in the presence or absence of mitomycin C (Roche, Penzberg, Germany) at the indicated concentrations 24 h later. Alternatively, cells were treated for 16 h with 20 ng/ml soluble recombinant FasL (Alexis, Enzo Life Sciences, Lörrach, Germany), 1 mg/ml anti-Flag M2 antibody (Sigma) for ligand crosslinking and 0.1 mg/ml cycloheximide (Roche). For the quantification of apoptosis, cells were harvested at the appropriate time points, washed with phosphate-buffered saline (PBS) and fixed in ice-cold 70% ethanol before overnight incubation at 4 1C. Cells were then stained for 20 min with propidium iodide (50 mg/ml) in 38 mM sodium citrate plus 10 mg/ml RNase A at room temperature in the dark, and flow cytometry was performed using a FACS Calibur (BD Biosciences, Heidelberg, Germany). Apoptotic cells with hypoploid DNA content were quantified in the 'subG1' region of the cell-cycle profile.
Fluorimetric analysis of Caspase-3 activity. For PEI-transfected HEK 293T cells, the Casp-3/CPP32 Fluorometric Assay Kit from BioVision (BioCAT GmbH, Heidelberg, Germany) was used according to the manufacturer's instructions. Briefly, 5 Â 10 6 cells were harvested and washed once with ice-cold 1 Â PBS. After shock-freezing in liquid nitrogen, the pellets were stored at À80 1C.
To assay for caspase activity, cell pellets were thawed on ice, re-suspended in 50 ml of cell lysis buffer and incubated for an additional 10 min on ice. To induce apoptosome formation, lysates were incubated with 50 mg/ml Cyt c (Sigma) and 1 mM dATP (Sigma) for 15 min at 37 1C. Next, 50 ml of 2 Â reaction buffer (containing 10 mM DTT) was added to each sample. After resuspending by pipetting (100 ml end volume), the Caspase-3-specific substrate Ac-DEVD-AFC (N-actyl-AspGlu-Val-Asp-7-amino-4-trifluoromethyl-coumarin) was added with a final concentration of 30 mM, and samples were transferred to a 96-well plate in triplicates (33 ml in each well). Fluorescence was measured during 2 h of incubation at 37 1C using a fluorometer (FLUOstar OPTIMA, BMG Labtechnologies GmbH, Ortenberg, Germany).
For transduced MCF-7/Casp-3 cells, the fluorometric Caspase-3 activity kit from Sigma Aldrich was used according to the manufacturer's instructions. Briefly, 5 Â 10 4 transduced cells were seeded in triplicates into clear-bottom black 96-well plates (mclear, Greiner BioOne, Frickenhausen, Germany) and allowed to adhere for at least 6 h. Apoptosis was induced with FasL, staurosporine (Calbiochem, Merck, Darmstadt, Germany) or doxorubicin (Sigma; concentrations are indicated in the figure legends) over night. Plates were centrifuged with 1000 r.p.m. at room temperature for 5 min, and supernatants were then discarded. Lysis buffer (50 ml) was added to each well, and lysis was performed at room temperature on a shaking platform (350 r.p.m.). Assay buffer (150 ml) containing 17 mM Caspase-3 fluorimetric substrate (Ac-DEVD-AFC) was added to each well, and fluorescence was measured during 2 h of incubation at 37 1C in a fluorometer (FLUOstar OPTIMA, BMG Labtechnologies GmbH).
CathD cleavage of recombinant purified Aven-10xHis. Two to four 14-cm dishes with 3 Â 10 6 HEK 293T cells were transfected with 20 mg each of pcDNA3.1 flAven-10xHis. After 48 h, cells were harvested and incubated in 5 ml Hislysis buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 10 mM imidazole, 5% glycerol and 0.5% NP-40) for 30 min on ice before sonification (three 10 s pulses, strength 4, sonifier from Branson, Dietzenbach, Germany). Lysates were cleared by centrifugation at 14 000 r.p.m. and 4 1C for 10 min, and supernatants were added to 250 ml Ni-NTA beads (Qiagen, Hilden, Germany) prewashed in His-lysis buffer. Binding was performed at 4 1C for 1-2 h. Supernatants were discarded and beads were washed three times with His-lysis buffer containing increasing concentrations of imidazole (20, 50 and 70 mM; Roth). Protein was eluted from the beads in a total volume of 200 ml for 20 min at 4 1C using His-lysis buffer with 200 mM imidazole.
Purified Aven protein (2 mg) was added to the CathD cleavage buffer (20 mM MES pH 6.5, 50 mM NaCl, 1 mM DTT) in a total volume of 20 ml, and 0.3 units of human recombinant CathD (Calbiochem) were added to each reaction. Digestion was performed at 37 1C with constant shaking (300 r.p.m.), and samples were harvested by adding 5 Â SDS-PAGE sample buffer and heating to 95 1C for 5 min at various time points. For the controls, one sample was incubated without CathD, and one sample was supplemented with 50 mM pepstatin A before incubation. Samples were separated on 10% SDS-PAGE gels, blotted to nitrocellulose (Schleicher&Schuell, Dassel, Germany), and full-length and cleaved C-terminal Aven were detected with anti-His-tag-antibody.
CathD digest of Aven-10xHis and mass spectrometry analysis. To map the CathD cleavage sites of the Aven molecule, purified Aven protein (5 mg) was diluted in 50 ml of CathD cleavage buffer (50 mM MES, 50 mM sodium phosphate pH 7.4, 150 mM NaCl, 1 mM DTT, 1 mM EDTA; adjusted to pH 4.5 with 1N HCl). Recombinant human CathD (400 ng) was added to the protein mixture and samples were then incubated on a shaking platform at 100 r.p.m. for 10 or 30 min at 37 1C. The negative controls were incubated for 30 min either without the addition of CathD or with the addition of CathD and 10 mM pepstatin A. After protease incubation, all samples were supplemented with 50 mM sodium phosphate pH 8.0 to a final volume of 500 ml and solid guanidinium hydrocholoride (2 M final concentration). To label primary a-and e-amines, 6.25 mmol N-hydroxysuccinimide trideutero-acetate (NHS AcD 3 -acetate, synthesized in-house as previously described 35 was added to each sample followed by a 2-h incubation at 30 1C. Each sample was then supplemented with 12.5 mmol glycine and 37.5 mmol hydroxylamine for a 20-min incubation at 30 1C to quench excess NHS AcD 3 -acetate and reverse possible O-acetylation, respectively. Proteins were then desalted on disposable NAP-5 columns (GE Healthcare BioSciences, Munich, Germany) and collected in 1 ml of 50 mM ammonium bicarbonate pH 8.0. Next, samples were boiled for 5 min, placed on ice for 5 min and digested overnight at 37 1C with 2 mg trypsin (Promega Sequencing-Grade Modified Trypsin, Promega, Mannheim, Germany). Without pre-enrichment for Nterminal peptides, 100 ml of each sample was acidified with 2 ml formic acid and applied for LC-MS/MS analysis using a Thermo LTQ-Orbitrap XL mass spectrometer (2.5 ml of sample was injected for each reading), which was operated as previously described. 36 Recorded MS/MS spectra data were examined using a locally installed version of the Mascot algorithm in the human subsection of the Swiss-Prot database. For this analysis, the following search parameters were used: the protease setting was set to semi-ArgC/P with up to two missed cleavages allowed, fixed trideutero-acetate modification of lysine residues, variable acetate and trideutero-acetate modification of peptide N-termini, variable oxidation of methionine residues to methionine-sulfoxide, variable formation of pyroglutamate from N-terminal glutamine residues, precursor mass tolerance of 10 p.p.m. and fragment mass tolerance of 0.5 Da. Only the peptides that were ranked first and scored above the Mascot identity threshold at 95% confidence interval were withheld. Aven peptides that were trideutero-acetylated at the a-amine were used to report CathD cleavage sites.
